Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Telo Genomics Corp TDSGF


Primary Symbol: V.TELO

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display... see more

Recent & Breaking News (TSXV:TELO)

3D Signatures Advances Hodgkin’s Lymphoma Test

GlobeNewswire June 8, 2017

3D Signatures Inc. Reports Third Quarter 2017 Financial Results

GlobeNewswire May 31, 2017

3D Signatures Announces Change to Its Board of Directors

GlobeNewswire May 5, 2017

3D Signatures Receives First Prostate Cancer Blood Samples for Precise Clinical Trial

GlobeNewswire April 27, 2017

3D Signatures Announces Relocation to MaRS Discovery District in Toronto

GlobeNewswire April 18, 2017

3D Signatures Announces Appointment of Dr. Kevin Little as Chief Scientific Officer

GlobeNewswire April 11, 2017

3D Signatures Completes Assay Validation for Hodgkin’s Lymphoma Test

GlobeNewswire March 29, 2017

3D Signatures’ TeloView™ Software Identifies and Stages Patients With Alzheimer’s Disease From a Cheek Swab

GlobeNewswire March 21, 2017

3D Signatures Makes Final Patent Payment

GlobeNewswire March 14, 2017

3D Signatures Inc. Reports Second Quarter 2017 Financial Results

GlobeNewswire March 2, 2017

3D Signatures Inc. Initiates Hodgkin’s Lymphoma Validation Program

GlobeNewswire February 23, 2017

3D Signatures to Present Positive Results for Prostate Cancer Liquid Biopsy

GlobeNewswire February 21, 2017

3D Signatures Inc. Adds Medical Diagnostic Expert to Business Advisory Board

GlobeNewswire February 15, 2017

3D Signatures Inc. to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference

GlobeNewswire January 25, 2017

3D Signatures Inc. Announces Grant of Stock Options

GlobeNewswire January 18, 2017

3D Signatures Inc. Provides Further Detail on Kilmer Lucas Engagement

GlobeNewswire January 16, 2017

New Study Shows 3D Signatures' Telomere Analysis May Be an Effective Biomarker for Monitoring High Risk Prostate Cancer Patients

MarketWire Canada January 9, 2017

3D Signatures Inc. Announces Closing of Third and Final Tranche of Fully Subscribed Brokered Private Placement

MarketWire Canada January 6, 2017

3D Signatures Appoints Accomplished Healthcare Veteran as Chief Business Officer

MarketWire Canada January 6, 2017

3D Signatures Common Shares Now Listed on the OTCQB and Frankfurt Stock Exchanges

MarketWire Canada January 4, 2017